# Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis

> **NCT06444113** · PHASE4 · ACTIVE_NOT_RECRUITING · sponsor: **Novartis Pharmaceuticals** · enrollment: 24 (actual)

## Conditions studied

- Multiple Sclerosis

## Interventions

- **DRUG:** Ofatunumab

## Key facts

- **NCT ID:** NCT06444113
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-11-25
- **Primary completion:** 2026-05-18
- **Final completion:** 2026-10-29
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06444113

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06444113, "Concentration of Ofatumumab in the Breast Milk of Lactating Women With Relapsing Forms of Multiple Sclerosis". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT06444113. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*